Saion Mukherjee

Thank you for taking my question. Can you update on the capacity utilization at Unit 1, 2 and Neo Anthem as of first quarter and how should we think about utilization levels in these un its change in the next 3 years? Any timeline with respect to regulatory inspection required for Unit 3 by US FDA or European authorities?

Thank you. Just one clarification, with the increased utilization at Neo Anthem is primarily the shifting of some production from the existing units to Neo Anthem, is that what is happening?

Thank you, sir. So , just one clarification, you mentioned one new Big Pharma significant contribution possible. Any timeline that you have, like in how much time we will see that traction showing up in numbers?